U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07361107) titled 'Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)' on Dec. 10, 2025.
Brief Summary: This is a single-center, non-randomized, open-label, single-arm pilot study investigating the systemic immune response to histotripsy in patients with colorectal cancer with liver metastasis. Histotripsy is an FDA-approved, non-invasive therapeutic modality for the treatment of liver tumors, including both primary and metastatic lesions. In this study, investigators aim to evaluate the kinetics of peripheral T-cell response following histotripsy of colorectal cancer liver metastases (CRCLM). Given the well-do...